In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Celldex Therapeutics Inc. (NASDAQ:CLDX) reported that Columbia Wanger Asset Management Llc. has picked up 6,195,855 of common stock as of 2017-02-10.

The acquisition brings the aggregate amount owned by Columbia Wanger Asset Management Llc. to a total of 6,195,855 representing a 5.1% stake in the company.

For those not familiar with the company, Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company’s pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

A glance at Celldex Therapeutics Inc. (NASDAQ:CLDX)’s key stats reveals a current market capitalization of 416.17 million based on 122.28 million shares outstanding and a price at last close of $3.45 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-08-25, Ellberger picked up 5,000 at a purchase price of $14.00. This brings their total holding to 53,500 as of the date of the filing.

On the sell side, the most recent transaction saw Catlin unload 25,000 shares at a sale price of $18.00. This brings their total holding to 35,109.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Celldex Therapeutics Inc. (NASDAQ:CLDX) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.